stoxline Quote Chart Rank Option Currency Glossary
NightHawk Biosciences, Inc. (NHWK)
0.4135  0.034 (8.96%)    02-05 15:58
Open: 0.3721
High: 0.43
Volume: 161,222
Pre. Close: 0.3795
Low: 0.3666
Market Cap: 11(M)
Technical analysis
2024-02-23 4:38:24 PM
Short term     
Mid term     
Targets 6-month :  0.46 1-year :  0.51
Resists First :  0.39 Second :  0.44
Pivot price 0.36
Supports First :  0.32 Second :  0.27
MAs MA(5) :  0.33 MA(20) :  0.36
MA(100) :  0.39 MA(250) :  0.59
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  7.3 D(3) :  7
RSI RSI(14): 40.8
52-week High :  1.02 Low :  0.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NHWK ] has closed above bottom band by 13.3%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.36 - 0.36 0.36 - 0.36
Low: 0.32 - 0.32 0.32 - 0.32
Close: 0.33 - 0.33 0.33 - 0.33
Company Description

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Headline News

Tue, 20 Feb 2024
NightHawk Biosciences (NYSE:NHWK) Share Price Passes Above 50 Day Moving Average of $0.38 - Defense World

Tue, 06 Feb 2024
NightHawk Biosciences Rebrands as Scorpius Holdings Focusing on Biomanufacturing Services - Best Stocks

Tue, 06 Feb 2024
NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX ... - Yahoo Finance

Mon, 08 Jan 2024
Scorpius Holdings Inc Announces Name Change and Leadership Promotions - Best Stocks

Mon, 08 Jan 2024
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a ... - Yahoo Finance

Mon, 08 Jan 2024
NightHawk Biosciences changing name to Scorpius, ticker to SCPX (NYSE:NHWK) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out -26 (M)
Shares Float 0 (M)
Held by Insiders 2.608e+007 (%)
Held by Institutions 2.474e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.05
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 529.4 %
Return on Equity (ttm) -36.1 %
Qtrly Rev. Growth 8.24e+006 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -4.764e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -0.17
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 303690
Forward Dividend 292440
Dividend Yield 91999400%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android